Hospital
North Carolina Baptist Hospital
North Carolina Baptist Hospital was paid $138.19M by Medicaid between Jan 2018 and Dec 2024, across 416 billing codes. Its largest line is 99284, emergency room visit (serious) — 27% of everything it billed.
33Billing provider infoNORTH CAROLINA BAPTIST HOSPITAL
WINSTON SALEM, NC 27157
WINSTON SALEM, NC 27157
33aNPI1144211301assigned 11/04/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$138.19M
24GClaims2,386,757
24DCodes billed416
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in North Carolina
Rank by total paid#2 of 92
Median peer was paid$11.47M
This provider vs. median12×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 327,084 | $12.72M | |
| 2019 | 322,824 | $12.86M | |
| 2020 | 246,004 | $10.01M | |
| 2021 | 418,816 | $22.88M | |
| 2022 | 450,204 | $28.33M | |
| 2023 | 314,940 | $26.02M | |
| 2024incomplete | 306,885 | $25.38M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 27% | 74,519 | 69,016 | $37.10M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 20% | 84,063 | 78,848 | $27.02M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 9.9% | 393,234 | 354,406 | $13.67M |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 9.6% | 1,309 | 1,067 | $13.23M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.8% | 9,992 | 8,647 | $6.62M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.7% | 22,581 | 21,472 | $3.80M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.3% | 103,789 | 92,574 | $3.18M |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 1.8% | 1,556 | 1,500 | $2.44M |
| J0475 | Injection, baclofen, 10 mg | 1.2% | 1,302 | 1,227 | $1.69M |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 7,974 | 6,952 | $1.24M |
| 0240U | <1% | 6,215 | 5,717 | $1.14M | |
| 80053 | Comprehensive metabolic panel | <1% | 137,945 | 110,350 | $1.13M |
404 more codes
| J2323 | Injection, natalizumab, 1 mg | <1% | 462 | $1.11M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 156,453 | $1.11M |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 34,806 | $970K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 34,774 | $968K |
| J3490 | Unclassified drugs | <1% | 62,374 | $838K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 9,054 | $802K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 4,130 | $801K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 15,411 | $741K |
| G0378 | Hospital observation service, per hour | <1% | 3,252 | $716K |
| 76770 | <1% | 3,456 | $576K | |
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | <1% | 123 | $548K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 20,926 | $544K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 975 | $531K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 30,877 | $483K |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 554 | $457K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 15,606 | $424K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 9,060 | $379K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,645 | $348K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 33,472 | $345K |
| D0150 | Comprehensive oral evaluation - new or established patient | <1% | 475 | $313K |
| 36415 | Collection of venous blood by venipuncture | <1% | 115,044 | $311K |
| 80061 | Lipid panel | <1% | 22,475 | $291K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 3,186 | $267K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,230 | $253K |
| 87632 | <1% | 2,535 | $251K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 3,669 | $232K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,407 | $219K |
| 87081 | <1% | 29,153 | $216K | |
| D0220 | Intraoral - periapical first radiographic image | <1% | 426 | $203K |
| 87088 | <1% | 24,376 | $199K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 5,522 | $198K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,821 | $197K |
| 82728 | <1% | 17,254 | $193K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 1,238 | $191K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 5,088 | $189K |
| 85027 | <1% | 37,409 | $187K | |
| D0230 | Intraoral - periapical each additional radiographic image | <1% | 401 | $185K |
| 82105 | <1% | 9,539 | $180K | |
| 62370 | <1% | 1,224 | $176K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,777 | $166K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,750 | $165K |
| 84439 | <1% | 16,574 | $164K | |
| 64644 | <1% | 1,173 | $161K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 2,740 | $155K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,441 | $154K |
| 82677 | <1% | 7,138 | $153K | |
| 92060 | <1% | 5,575 | $152K | |
| 84466 | <1% | 14,729 | $148K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 182 | $145K |
| 81001 | <1% | 39,037 | $141K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 119 | $133K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,337 | $131K |
| 86850 | <1% | 6,220 | $131K | |
| 93320 | <1% | 350 | $127K | |
| 86003 | <1% | 783 | $123K | |
| 86336 | <1% | 7,140 | $118K | |
| 59025 | Fetal non-stress test | <1% | 1,684 | $116K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,361 | $106K |
| 82607 | <1% | 9,090 | $103K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,547 | $102K |
| 86803 | <1% | 7,212 | $102K | |
| 86762 | <1% | 6,258 | $100K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,415 | $100K |
| 87340 | <1% | 10,499 | $99K | |
| 86592 | <1% | 21,253 | $98K | |
| 93325 | <1% | 561 | $97K | |
| 83655 | <1% | 5,669 | $96K | |
| 88142 | <1% | 4,129 | $92K | |
| 87536 | <1% | 3,170 | $92K | |
| 92567 | <1% | 3,427 | $89K | |
| A9270 | Non-covered item or service | <1% | 164,278 | $89K |
| 82043 | <1% | 11,732 | $86K | |
| 86787 | <1% | 5,983 | $86K | |
| J1726 | Injection, hydroxyprogesterone caproate, (makena), 10 mg | <1% | 133 | $80K |
| 84702 | <1% | 8,635 | $80K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 97 | $78K |
| 81025 | <1% | 9,829 | $78K | |
| 83540 | <1% | 14,823 | $76K | |
| 86140 | <1% | 11,420 | $75K | |
| 87631 | <1% | 840 | $74K | |
| 87070 | <1% | 6,927 | $73K | |
| 54161 | <1% | 80 | $72K | |
| 87507 | <1% | 420 | $71K | |
| 92523 | <1% | 615 | $70K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 11,514 | $69K |
| 72082 | <1% | 699 | $67K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 150 | $63K |
| 82947 | <1% | 11,478 | $63K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 6,989 | $61K |
| 64645 | <1% | 638 | $60K | |
| 87486 | <1% | 2,539 | $60K | |
| 92610 | <1% | 704 | $59K | |
| 95873 | <1% | 663 | $56K | |
| 81003 | <1% | 18,433 | $55K | |
| 90870 | <1% | 120 | $54K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 1,094 | $54K |
| 80069 | <1% | 6,856 | $51K | |
| 55175 | <1% | 70 | $50K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 18,211 | $49K |
| Q3014 | Telehealth originating site facility fee | <1% | 4,304 | $49K |
| 0002A | <1% | 886 | $49K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 942 | $48K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,915 | $48K |
| 54300 | <1% | 71 | $48K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,728 | $47K |
| 14040 | <1% | 94 | $47K | |
| 84100 | <1% | 21,749 | $47K | |
| 85652 | <1% | 13,256 | $46K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 81 | $46K |
| 83516 | <1% | 2,868 | $45K | |
| 73521 | <1% | 556 | $45K | |
| 74018 | <1% | 1,077 | $44K | |
| 83735 | <1% | 26,222 | $43K | |
| 85045 | <1% | 8,729 | $42K | |
| 0001A | <1% | 820 | $42K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,955 | $41K |
| 81229 | <1% | 50 | $41K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,490 | $40K |
| 82784 | <1% | 3,521 | $39K | |
| 92134 | <1% | 3,659 | $39K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,536 | $38K |
| 86901 | <1% | 5,664 | $37K | |
| 86900 | <1% | 5,652 | $36K | |
| 82042 | <1% | 6,208 | $35K | |
| 80197 | <1% | 9,173 | $35K | |
| 86361 | <1% | 1,973 | $35K | |
| 87077 | <1% | 5,488 | $34K | |
| 92587 | <1% | 431 | $34K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 557 | $34K |
| 86738 | <1% | 2,544 | $33K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 10,641 | $31K |
| 92579 | <1% | 225 | $31K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,180 | $30K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 537 | $30K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 160 | $27K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 475 | $27K |
| 91065 | <1% | 49 | $27K | |
| 86360 | <1% | 490 | $25K | |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 27 | $25K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 192 | $24K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 988 | $23K |
| 84550 | <1% | 7,911 | $23K | |
| 73100 | <1% | 320 | $22K | |
| 90686 | <1% | 1,615 | $22K | |
| D0274 | Bitewings - four radiographic images | <1% | 41 | $21K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 821 | $21K |
| 87799 | <1% | 2,921 | $21K | |
| 80076 | <1% | 4,598 | $21K | |
| 83615 | <1% | 4,434 | $21K | |
| 91122 | <1% | 52 | $20K | |
| 82340 | <1% | 3,130 | $20K | |
| 82570 | <1% | 4,914 | $19K | |
| 73610 | <1% | 353 | $19K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,716 | $19K |
| 73070 | <1% | 254 | $19K | |
| 80081 | <1% | 171 | $18K | |
| 92201 | <1% | 902 | $18K | |
| 87186 | <1% | 3,497 | $17K | |
| 83970 | <1% | 753 | $17K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,177 | $17K |
| 82746 | <1% | 1,524 | $17K | |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | <1% | 25 | $17K |
| 97803 | <1% | 520 | $16K | |
| 83020 | <1% | 936 | $16K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 24 | $16K |
| 84481 | <1% | 866 | $16K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,317 | $16K |
| 86160 | <1% | 413 | $16K | |
| 87497 | <1% | 2,773 | $16K | |
| 73090 | <1% | 206 | $15K | |
| 87430 | <1% | 1,037 | $15K | |
| 87480 | <1% | 726 | $15K | |
| 87660 | <1% | 726 | $15K | |
| 86141 | <1% | 1,004 | $15K | |
| 0072A | <1% | 274 | $15K | |
| J0897 | Injection, denosumab, 1 mg | <1% | 26 | $14K |
| 93296 | <1% | 681 | $14K | |
| 84403 | <1% | 536 | $14K | |
| 87522 | Neg quan hep c or qual rna | <1% | 646 | $14K |
| 86704 | <1% | 1,983 | $14K | |
| 92526 | <1% | 138 | $14K | |
| 86708 | <1% | 1,850 | $14K | |
| 92560 | <1% | 33 | $13K | |
| 36430 | <1% | 33 | $13K | |
| 82652 | <1% | 288 | $13K | |
| 84156 | <1% | 4,821 | $13K | |
| 76801 | <1% | 118 | $13K | |
| 76820 | <1% | 142 | $12K | |
| 0071A | <1% | 244 | $12K | |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 129 | $12K |
| 81514 | <1% | 400 | $12K | |
| 73630 | <1% | 196 | $12K | |
| 88300 | <1% | 716 | $12K | |
| 83690 | <1% | 3,417 | $12K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 72 | $12K |
| 89220 | <1% | 196 | $11K | |
| J2704 | Injection, propofol, 10 mg | <1% | 977 | $11K |
| 20610 | <1% | 161 | $10K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 4,970 | $10K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,269 | $10K |
| 87205 | <1% | 1,996 | $10K | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 3,772 | $10K |
| 94010 | <1% | 107 | $9K | |
| 83880 | <1% | 978 | $9K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 129 | $9K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 8,476 | $8K |
| 92133 | <1% | 644 | $8K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 206 | $8K |
| 97760 | <1% | 99 | $8K | |
| 93886 | <1% | 35 | $8K | |
| 82962 | <1% | 2,071 | $8K | |
| 83525 | <1% | 551 | $7K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,567 | $7K |
| 92524 | <1% | 74 | $7K | |
| 83001 | <1% | 303 | $7K | |
| 92015 | Determination of refractive state | <1% | 618 | $7K |
| 27096 | <1% | 13 | $7K | |
| 86706 | <1% | 1,448 | $7K | |
| 87210 | <1% | 2,124 | $7K | |
| A4217 | Sterile water/saline, 500 ml | <1% | 992 | $7K |
| 86747 | <1% | 409 | $7K | |
| 86039 | <1% | 560 | $7K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 61 | $6K |
| 82950 | <1% | 1,194 | $6K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 62 | $6K |
| 96127 | <1% | 379 | $6K | |
| 73590 | <1% | 85 | $6K | |
| 92557 | <1% | 115 | $6K | |
| 80047 | <1% | 1,649 | $6K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 39 | $6K |
| 86480 | <1% | 98 | $6K | |
| 92552 | <1% | 168 | $6K | |
| 85610 | <1% | 3,481 | $5K | |
| 92083 | <1% | 247 | $5K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 15 | $5K |
| 86677 | <1% | 271 | $4K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,486 | $4K |
| 83921 | <1% | 478 | $4K | |
| 84300 | <1% | 843 | $4K | |
| 83002 | <1% | 164 | $4K | |
| 74022 | <1% | 58 | $4K | |
| 92558 | <1% | 25 | $4K | |
| 92226 | <1% | 95 | $4K | |
| 80050 | General health panel | <1% | 114 | $4K |
| 90656 | <1% | 180 | $4K | |
| 86709 | <1% | 606 | $4K | |
| 84133 | <1% | 816 | $3K | |
| 74230 | <1% | 26 | $3K | |
| 87420 | <1% | 189 | $3K | |
| 36591 | <1% | 161 | $3K | |
| 92582 | <1% | 39 | $3K | |
| 83883 | <1% | 200 | $3K | |
| 84484 | <1% | 1,840 | $3K | |
| 84436 | <1% | 685 | $3K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 46 | $3K |
| 82977 | <1% | 478 | $3K | |
| 86334 | <1% | 180 | $3K | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 834 | $3K |
| 96900 | <1% | 275 | $3K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,535 | $3K |
| 82948 | <1% | 582 | $3K | |
| 73030 | <1% | 39 | $3K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,074 | $2K |
| 73130 | <1% | 34 | $2K | |
| 93298 | <1% | 133 | $2K | |
| 97763 | <1% | 40 | $2K | |
| J9370 | Vincristine sulfate, 1 mg | <1% | 198 | $2K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 398 | $2K |
| 92555 | <1% | 82 | $2K | |
| 97162 | <1% | 29 | $2K | |
| 82747 | <1% | 235 | $2K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 643 | $2K |
| 0011A | <1% | 38 | $2K | |
| 84146 | <1% | 115 | $2K | |
| 0012A | <1% | 52 | $2K | |
| 91322 | <1% | 44 | $2K | |
| 29450 | <1% | 60 | $2K | |
| 82670 | <1% | 73 | $2K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 51 | $2K |
| 84479 | <1% | 442 | $2K | |
| 87510 | <1% | 726 | $2K | |
| 82330 | <1% | 149 | $2K | |
| 82550 | <1% | 763 | $2K | |
| 0052A | <1% | 32 | $2K | |
| 93242 | <1% | 13 | $2K | |
| 86430 | <1% | 314 | $2K | |
| 77072 | <1% | 12 | $2K | |
| 95250 | <1% | 13 | $2K | |
| 83520 | <1% | 42 | $2K | |
| 85018 | <1% | 1,064 | $2K | |
| 82565 | <1% | 404 | $2K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 82 | $2K |
| 82248 | <1% | 252 | $2K | |
| 73552 | <1% | 14 | $1K | |
| 25600 | <1% | 13 | $1K | |
| 86038 | <1% | 133 | $1K | |
| 92650 | <1% | 21 | $1K | |
| 86923 | <1% | 46 | $1K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 27 | $1K |
| 86225 | <1% | 70 | $1K | |
| 54150 | <1% | 13 | $1K | |
| 73562 | <1% | 27 | $1K | |
| 85007 | <1% | 253 | $1K | |
| 31231 | <1% | 27 | $1K | |
| 84480 | <1% | 91 | $1K | |
| 84165 | <1% | 161 | $1K | |
| 85730 | <1% | 1,626 | $1K | |
| 91200 | <1% | 25 | $1K | |
| 36416 | <1% | 611 | $1K | |
| 90651 | <1% | 12 | $1K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 3,305 | $1K |
| 92611 | <1% | 12 | $1K | |
| 84450 | <1% | 223 | $1K | |
| 82150 | <1% | 177 | $1K | |
| 81243 | <1% | 27 | $1K | |
| 86376 | <1% | 81 | $1K | |
| 64615 | <1% | 13 | $1K | |
| 82247 | <1% | 224 | $1K | |
| 73110 | <1% | 12 | $996.49 | |
| 64643 | <1% | 53 | $990.10 | |
| 84560 | <1% | 154 | $987.78 | |
| 82533 | <1% | 125 | $960.16 | |
| 84630 | <1% | 40 | $948.38 | |
| 84460 | <1% | 400 | $943.66 | |
| 92556 | <1% | 29 | $838.68 | |
| 84425 | <1% | 34 | $793.80 | |
| 0004A | <1% | 15 | $756.38 | |
| 82088 | <1% | 13 | $693.16 | |
| 86800 | <1% | 26 | $677.86 | |
| 95874 | <1% | 58 | $665.37 | |
| 84305 | <1% | 29 | $664.54 | |
| 83498 | <1% | 16 | $649.32 | |
| 86364 | <1% | 272 | $639.72 | |
| 86235 | <1% | 18 | $625.52 | |
| 82378 | <1% | 21 | $625.21 | |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 470 | $623.87 |
| 88346 | <1% | 15 | $618.80 | |
| 96161 | <1% | 135 | $606.53 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,090 | $599.02 |
| 96381 | <1% | 53 | $598.00 | |
| 90715 | <1% | 17 | $530.73 | |
| 97597 | <1% | 18 | $522.47 | |
| 84681 | <1% | 28 | $519.75 | |
| 90480 | <1% | 44 | $502.88 | |
| 84207 | <1% | 14 | $455.13 | |
| 31575 | <1% | 12 | $429.46 | |
| 86301 | <1% | 18 | $417.34 | |
| 83519 | <1% | 17 | $384.44 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 193 | $384.30 |
| 84244 | <1% | 12 | $345.24 | |
| 85240 | <1% | 14 | $334.65 | |
| 86255 | <1% | 15 | $323.03 | |
| 83521 | <1% | 13 | $318.74 | |
| 96380 | <1% | 14 | $317.57 | |
| 86830 | <1% | 27 | $294.75 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 120 | $287.45 |
| 88720 | <1% | 29 | $239.46 | |
| 92136 | <1% | 12 | $237.96 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 690 | $217.92 |
| 87338 | <1% | 13 | $215.04 | |
| A0425 | Ground mileage, per statute mile | <1% | 116 | $213.45 |
| 90662 | <1% | 62 | $199.48 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 136 | $190.59 |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | <1% | 13 | $189.05 |
| 82785 | <1% | 13 | $184.68 | |
| 80164 | <1% | 86 | $180.53 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 15 | $176.34 |
| 86831 | <1% | 13 | $168.44 | |
| 85014 | <1% | 142 | $157.91 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 42 | $131.55 |
| 81002 | <1% | 42 | $127.60 | |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 47 | $99.72 |
| Q0111 | Wet mounts, including preparations of vaginal, cervical or skin specimens | <1% | 159 | $88.75 |
| 83605 | <1% | 1,196 | $56.73 | |
| 90682 | <1% | 15 | $32.97 | |
| 80143 | <1% | 122 | $27.50 | |
| 80179 | <1% | 116 | $13.27 | |
| G0008 | Administration of influenza virus vaccine | <1% | 175 | $8.13 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 27 | $6.05 |
| D1206 | Topical application of fluoride varnish | <1% | 14 | $2.52 |
| 91300 | 0% | 1,044 | $0.00 | |
| 82140 | 0% | 81 | $0.00 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 144 | $0.00 |
| 85384 | 0% | 550 | $0.00 | |
| 89051 | 0% | 63 | $0.00 | |
| 80202 | 0% | 1,208 | $0.00 | |
| 84295 | 0% | 37 | $0.00 | |
| 87102 | 0% | 43 | $0.00 | |
| 84145 | 0% | 56 | $0.00 | |
| 87324 | 0% | 22 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 12 | $0.00 |
| 80301 | 0% | 33 | $0.00 | |
| 87040 | 0% | 1,482 | $0.00 | |
| 91301 | 0% | 107 | $0.00 | |
| 80329 | 0% | 27 | $0.00 | |
| 84132 | 0% | 67 | $0.00 | |
| 85379 | 0% | 404 | $0.00 | |
| 82803 | 0% | 358 | $0.00 | |
| 91307 | 0% | 138 | $0.00 | |
| A0426 | Ambulance service, advanced life support, non-emergency transport, level 1 (als 1) | 0% | 39 | $0.00 |
| 84153 | 0% | 13 | $0.00 | |
| 91305 | 0% | 17 | $0.00 | |
| 80320 | 0% | 27 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 160 | $-0.01 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWHEATLEY, CATHLEEN (PRESIDENT, AH WFB & DMC)
| Provider | Location | Paid |
|---|---|---|
| Davie Medical Center | Bermuda Run, NC | $3.68M |
| North Carolina Baptist Hospital | Winston Salem, NC | $653K |
| North Carolina Baptist Hospital | Winston Salem, NC | $290K |
| North Carolina Baptist Hospital | Winston Salem, NC | $0.00 |
| North Carolina Baptist Hospital | Winston Salem, NC | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.